Responsive image

SLAS2015 Short Courses

Introduction to the Derivation and Maintenance of Human Induced Pluripotent Stem Cells

This course will provide an overview on the basic biology and laboratory techniques required derive and maintain human induced pluripotent stem cell (iPS) lines from skin fibroblasts. Additional topics will include characterization assays for iPS and Embryonic Stem cells (ES) with emphasis on the use of fluorescence activated cell sorting (FACS) and flow cytometry (FCM) and protocols for the derivation of neural lineage cell lines.

Who Should Attend:

How You Will Benefit From This Course:

Course Topics:

Instructor Name(s)/Affiliation(s):

David J Kahler — NYU Langone Medical Center
Justin Ichida — University of Southern California
Kelvin Lam — Simplex Pharma Advisors, Inc.

Instructor Bios:

David J Kahler

David Kahler earned his Ph.D. in Molecular Medicine and Immunology from the Medical College of Georgia in the lab of Andrew Mellor, where he studied the phenotype, function, and lineage of a rare subset of immunomodulatory dendritic cells found in humans and mice. While at the New York Stem Cell Foundation, Dr. Kahler served as the Director of the Flow Cytometry Core and Drug Discovery laboratories, and as Director of Laboratory Automation where he developed FCM/FACS based and automated technologies for the derivation, characterization and maintenance of human IPSC lines. Currently he is providing experimental design, assay development and data analysis support to clients of the RNAi HTS Core Laboratory at the NYU Langone Medical Center.

Justin Ichida

Justin Ichida completed his Ph.D. at Harvard Medical School in the laboratory of Dr. Jack Szostak and completed postdoctoral training in the laboratory of Dr. Kevin Eggan in the Department of Stem Cell and Regenerative Biology at Harvard University. Dr. Ichida was a New York Stem Cell Foundation Druckenmiller Fellow and a recipient of the NIH K99/R00 Pathway to Independence award from the National Institute of Neurological Disorders and Stroke. Currently, Justin is an Assistant Professor of Stem Cell Biology and Regenerative Medicine at the University of Southern California. His current research uses patient-specific disease models to define the mechanisms that lead to neuronal loss in ALS and frontotemporal dementia.

Kelvin Lam

Kelvin Lam is the Founder and President of Simplex Pharma Advisors, Inc., which offers consulting and business development services to biotech and CROs focusing on discovery and development including strategic planning. Currently he is the Director of Strategic Partnerships at Reaction Biology Corp and the Consultant-at-Large at Frontage Laboratories. Previously he held leadership positions at Blue Sky, Harvard Stem Cell Institute, Pfizer, Inc. and Scripted Pharmaceuticals. He is currently one of the Editors-in-Chief of Drug Discovery Today: Technologies (Elsevier) since 2003. Kelvin holds a B.A. in Chemistry from University of Hawaii and a Ph.D. in Biochemistry from Boston University. Kelvin completed his postdoctoral-training at Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center affiliated with Harvard Medical School.